1. Compared to chemotherapy, patients with inoperable hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer receiving the antibody-drug conjugate (ADC) datopotamab deruxtecan...
Read More
1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo;...
Read More
1. In a randomized double-blind placebo-controlled study, naldemedine use was associated with...
Read More
1. In this cohort study, women were less likely to return for mammogram screening if their...
Read More
1. Median PFS (5.6 months vs 5.6 months) and median OS (21.4 months vs 18.1 months) were similar...
Read More
1. In a retrospective analysis of 59,875 patients with metastatic prostate cancer, varying...
Read More
Patients found high value in integrating patient-reported outcomes into electronic health records, but expressed several areas of confusion.
Read More
1. The cumulative incidence of medication-related osteonecrosis of the jaw (MRONJ) in patients...
Read More
1. Patel and colleagues conducted a secondary economic analysis of a trial that assigned high-risk...
Read More
1. BrECADD resulted in significantly lower treatment-related morbidity than eBEACOPP. 2....
Read More
1. The median progression-free survival in the metastasis-directed therapy arm was 10.3 months vs...
Read More
1. In this modeling study, an alternative set of lung cancer screening criteria was more sensitive...
Read More
1. In the United States, the estimated annual cost of cancer screening was $43 billion, with...
Read More
1. When comparing corticosteroid peak dose for immunosuppression for anti–PD-1 plus...
Read More
1. Approximately 88% of patients with GD2-positive diffuse midline glioma or other progressive CNS...
Read More
1. Dose-dense adjuvant chemotherapy involving sequential epirubicin/cyclophosphamide and docetaxel...
Read More
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No...
Read More
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No...
Read More
1. Median overall survival was 41 months in the TKI-only group vs 40 months in the TKI-SRS group,...
Read More
1. Patients in the sintilimab group reported a significantly greater event-free survival at 36...
Read More
